Head to Head Comparison: Arbutus Biopharma Corporation (ABUS) and Its Peers
Arbutus Biopharma Corporation (NASDAQ: ABUS) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Arbutus Biopharma Corporation to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.
Insider & Institutional Ownership
67.0% of Arbutus Biopharma Corporation shares are owned by institutional investors. Comparatively, 48.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.0% of Arbutus Biopharma Corporation shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Arbutus Biopharma Corporation has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Arbutus Biopharma Corporation’s rivals have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.
This table compares Arbutus Biopharma Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Arbutus Biopharma Corporation||N/A||-28.97%||-21.71%|
|Arbutus Biopharma Corporation Competitors||-3,992.24%||-119.43%||-44.17%|
Valuation and Earnings
This table compares Arbutus Biopharma Corporation and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Arbutus Biopharma Corporation||$1.85 million||-$65.74 million||-1.21|
|Arbutus Biopharma Corporation Competitors||$207.80 million||-$2.19 million||-0.33|
Arbutus Biopharma Corporation’s rivals have higher revenue and earnings than Arbutus Biopharma Corporation. Arbutus Biopharma Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for Arbutus Biopharma Corporation and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Arbutus Biopharma Corporation||0||0||5||0||3.00|
|Arbutus Biopharma Corporation Competitors||790||2961||6466||145||2.58|
Arbutus Biopharma Corporation presently has a consensus target price of $15.67, suggesting a potential upside of 152.69%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.06%. Given Arbutus Biopharma Corporation’s stronger consensus rating and higher probable upside, research analysts plainly believe Arbutus Biopharma Corporation is more favorable than its rivals.
Arbutus Biopharma Corporation beats its rivals on 7 of the 12 factors compared.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.